# Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study

> **NCT07709624** · — · ACTIVE_NOT_RECRUITING · sponsor: **TTY Biopharm** · enrollment: 50 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** Minjuvi

## Key facts

- **NCT ID:** NCT07709624
- **Lead sponsor:** TTY Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2030-01-28
- **Final completion:** 2030-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709624, "Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07709624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*